 Nathan Dahl
Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 8 | 2024 | 348 | 3.570 |
Why?
| | Brain Neoplasms | 6 | 2025 | 1145 | 1.570 |
Why?
| | Brain Stem Neoplasms | 3 | 2023 | 81 | 1.490 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.890 |
Why?
| | Adrenoleukodystrophy | 1 | 2024 | 9 | 0.890 |
Why?
| | Astrocytoma | 2 | 2024 | 115 | 0.870 |
Why?
| | Pyrimidinones | 1 | 2023 | 102 | 0.770 |
Why?
| | Adenomatous Polyposis Coli | 2 | 2019 | 33 | 0.760 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2025 | 1336 | 0.730 |
Why?
| | Pyridones | 1 | 2023 | 158 | 0.730 |
Why?
| | Receptor, trkC | 1 | 2021 | 10 | 0.720 |
Why?
| | Receptor, trkB | 1 | 2021 | 30 | 0.710 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 60 | 0.690 |
Why?
| | Genes, APC | 2 | 2019 | 13 | 0.680 |
Why?
| | beta Catenin | 2 | 2019 | 225 | 0.670 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 36 | 0.660 |
Why?
| | Oncologists | 1 | 2020 | 35 | 0.650 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 142 | 0.630 |
Why?
| | Bevacizumab | 1 | 2019 | 128 | 0.610 |
Why?
| | Radiotherapy | 1 | 2019 | 185 | 0.600 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 477 | 0.600 |
Why?
| | Craniopharyngioma | 1 | 2019 | 74 | 0.590 |
Why?
| | Radiation Injuries | 1 | 2019 | 135 | 0.590 |
Why?
| | Brain Diseases | 1 | 2019 | 136 | 0.580 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 219 | 0.570 |
Why?
| | Pituitary Neoplasms | 1 | 2019 | 179 | 0.560 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 148 | 0.550 |
Why?
| | Chordoma | 1 | 2017 | 14 | 0.550 |
Why?
| | Skull Base Neoplasms | 1 | 2017 | 25 | 0.550 |
Why?
| | Tuberous Sclerosis | 1 | 2017 | 49 | 0.530 |
Why?
| | Gardner Syndrome | 1 | 2016 | 2 | 0.530 |
Why?
| | Fibroma | 1 | 2016 | 22 | 0.510 |
Why?
| | Mutation | 4 | 2024 | 3717 | 0.510 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2015 | 21 | 0.500 |
Why?
| | Histones | 2 | 2020 | 589 | 0.490 |
Why?
| | Chromosome Deletion | 1 | 2015 | 104 | 0.480 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 91 | 0.480 |
Why?
| | Niacinamide | 1 | 2015 | 75 | 0.470 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 88 | 0.470 |
Why?
| | Azacitidine | 1 | 2015 | 139 | 0.450 |
Why?
| | DNA Repair | 2 | 2024 | 210 | 0.360 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3186 | 0.320 |
Why?
| | Antineoplastic Agents | 2 | 2022 | 2046 | 0.320 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2015 | 596 | 0.310 |
Why?
| | Child | 7 | 2024 | 20884 | 0.290 |
Why?
| | Humans | 18 | 2025 | 129625 | 0.260 |
Why?
| | Sirtuin 2 | 1 | 2025 | 24 | 0.240 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 29 | 0.240 |
Why?
| | Gene Fusion | 1 | 2025 | 25 | 0.240 |
Why?
| | Child, Preschool | 5 | 2021 | 10490 | 0.230 |
Why?
| | Gene Rearrangement | 1 | 2025 | 148 | 0.220 |
Why?
| | Rhabdoid Tumor | 1 | 2025 | 95 | 0.220 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2024 | 52 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2023 | 35 | 0.210 |
Why?
| | Epigenomics | 2 | 2020 | 110 | 0.200 |
Why?
| | Cytidine Deaminase | 1 | 2023 | 57 | 0.200 |
Why?
| | Brain Stem | 1 | 2023 | 99 | 0.190 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2025 | 487 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2024 | 808 | 0.180 |
Why?
| | RNA Polymerase II | 1 | 2024 | 318 | 0.180 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2023 | 210 | 0.180 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 48 | 0.170 |
Why?
| | Fatal Outcome | 1 | 2021 | 300 | 0.170 |
Why?
| | Attitude to Death | 1 | 2020 | 67 | 0.160 |
Why?
| | Chromatin | 2 | 2020 | 479 | 0.160 |
Why?
| | Narration | 1 | 2020 | 57 | 0.160 |
Why?
| | Cerebellar Neoplasms | 1 | 2021 | 150 | 0.160 |
Why?
| | Medulloblastoma | 1 | 2021 | 191 | 0.150 |
Why?
| | Necrosis | 1 | 2019 | 232 | 0.150 |
Why?
| | Point Mutation | 1 | 2019 | 224 | 0.150 |
Why?
| | Apoptosis | 2 | 2024 | 2492 | 0.140 |
Why?
| | Female | 7 | 2021 | 68734 | 0.140 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1418 | 0.140 |
Why?
| | Rhabdomyoma | 1 | 2017 | 8 | 0.140 |
Why?
| | Angiomyolipoma | 1 | 2017 | 17 | 0.140 |
Why?
| | Dexamethasone | 1 | 2019 | 350 | 0.130 |
Why?
| | Heart Neoplasms | 1 | 2017 | 50 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3394 | 0.130 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2015 | 15 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2019 | 869 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 617 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2019 | 580 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 314 | 0.120 |
Why?
| | Mice | 4 | 2025 | 16961 | 0.110 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 611 | 0.110 |
Why?
| | Stem Cell Transplantation | 1 | 2015 | 164 | 0.110 |
Why?
| | Pilot Projects | 1 | 2019 | 1592 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1560 | 0.110 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 778 | 0.100 |
Why?
| | Male | 5 | 2021 | 63670 | 0.100 |
Why?
| | Kidney Neoplasms | 1 | 2017 | 348 | 0.100 |
Why?
| | Infant | 2 | 2017 | 8995 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1042 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2542 | 0.090 |
Why?
| | Phenotype | 1 | 2019 | 3075 | 0.090 |
Why?
| | Aging | 1 | 2020 | 1778 | 0.090 |
Why?
| | Neoplasms | 1 | 2025 | 2455 | 0.090 |
Why?
| | Animals | 4 | 2025 | 35391 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2017 | 829 | 0.080 |
Why?
| | Brain | 1 | 2020 | 2673 | 0.070 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 958 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2025 | 1891 | 0.060 |
Why?
| | Tissue Fixation | 1 | 2025 | 33 | 0.060 |
Why?
| | Paraffin Embedding | 1 | 2025 | 29 | 0.060 |
Why?
| | Formaldehyde | 1 | 2025 | 60 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2342 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2025 | 14522 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2025 | 313 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2021 | 2373 | 0.050 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 76 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 234 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 217 | 0.040 |
Why?
| | Adolescent | 1 | 2019 | 20412 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2021 | 131 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 593 | 0.040 |
Why?
| | Sulfonamides | 1 | 2022 | 497 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 286 | 0.040 |
Why?
|
|
Dahl's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|